Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,600.00
Bid: 1,598.00
Ask: 1,598.50
Change: -4.50 (-0.28%)
Spread: 0.50 (0.031%)
Open: 1,613.00
High: 1,613.00
Low: 1,589.00
Prev. Close: 1,604.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks fall as US inflation tops expectations

Tue, 13th Feb 2024 16:21

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

The FTSE 100 closed down 0.81% at 7,512.28 points, while the FTSE 250 fell 1.46% to settle at 18,923.83 points.

In currency markets, sterling was last down 0.21% on the dollar to trade at $1.2602, while it managed a modest uptick against the euro, gaining 0.33% to change hands at €1.1762.

"January consumer price inflation falling less than expected was enough of a catalyst to cut the equity rally short, push yields and the US dollar to two-month highs," said IG senior market analyst Axel Rudolph.

"Hopes for a Fed March rate cut have all but disappeared with the market now pricing in a 53% probability of a first cut being seen in June."

Rudolph said the Brent crude oil price was on track for its seventh straight day of gains, albeit at a slower pace, as investors mulled over the situation in the Middle East and supply concerns.

"US natural gas prices continue to slide, though, and hit their lowest level since July 2020 amid ample production levels and subdued demand due to more clement weather.

"The higher-than-expected US CPI reading provoked a sharp decline in the gold price with it now trading in two-month lows below the psychological $2,000 per troy ounce mark."

Unemployment rate decreases in UK, US inflation remains hot

In economic news, the Office for National Statistics reported that the unemployment rate for individuals aged 16 and over decreased to 3.8% in the three months to December, down from November's 4.2% and surpassing expectations for 4.0%.

However, the economic inactivity rate rose to 21.9%, primarily driven by the number of long-term sick individuals, which remained notably high.

Claimant counts for January increased by 14,100 on a monthly basis and 61,200 on a yearly basis, totalling 1.579 million.

Despite that, the employment rate stood at 75.0%.

Vacancies fell by 26,000 in the quarter, marking the 19th consecutive month of decline, although they still surpassed pre-pandemic levels.

Notably, wage growth exceeded forecasts, with average regular earnings for employees, excluding bonuses, rising by 6.2% annually, contrasting with predictions of 6.0%.

Including bonuses, wages grew by 5.8%.

Real-term annual growth for total pay was 1.4%, and 1.8% for regular pay.

However, the ONS expressed caution regarding labour force survey (LFS) estimates due to smaller sample sizes resulting from changes in methodology.

"Official data continue to suggest that the labour market remains tight, though their veracity remains questionable," said Samuel Tombs, chief UK economist at Pantheon Macroeconomics.

"The latest LFS estimates are based on the ONS' new population projections, but work to boost the response rate remains incomplete.

"Accordingly, the ONS says that the data should be treated with additional caution."

Tombs said the recent dip in the unemployment rate from its post-Covid peak of 4.3% in July looked "particularly suspect".

"Many surveys indicate that staff availability for vacancies has improved."

Meanwhile, inflation in the US surged beyond expectations in January, driven largely by increases in shelter prices.

According to the Bureau of Labor Statistics, the consumer price index rose by 3.1% year-on-year, exceeding the anticipated 2.9% increase and marking a continuation from December's 3.4% rise.

Core CPI, excluding food and energy prices, increased by 0.4% last month and stood at 3.9% higher annually, outpacing forecasts.

Notably, shelter prices, comprising a significant portion of the CPI, rose by 0.6% monthly, contributing substantially to the overall increase, while food prices also saw a 0.4% uptick.

However, energy prices declined by 0.9%, largely due to a 3.3% drop in gas prices.

Finally on data, there was a notable improvement in economic sentiment in Germany according to a closely-monitored survey.

The latest ZEW indicator of economic sentiment rose by 4.7 points in February, reaching 19.9, marking the seventh consecutive month of increase.

However, the indicator reflecting the current economic situation dropped by 4.4 points to -81.7, the lowest since June 2020, at the onset of the pandemic.

Housebuilders fall on jobs data, Aston Martin in the green

On London's equity markets, housebuilders and property-related firms were in focus, with Persimmon, Barratt Developments, Taylor Wimpey, and Rightmove all suffering losses of between 3.04% and 4.59%.

The downturn followed the release of the UK jobs data, which hinted at the potential for prolonged higher interest rates, thereby impacting sentiment in the property market.

Crest Nicholson, Redrow, Shaftesbury Capital, UK Commercial Property REIT, and Tritax EuroBox also registered declines in response to the aforementioned news, with Crest Nicholson tumbling 6.37%.

Travel firm TUI closed marginally lower despite reporting a positive quarterly underlying profit and affirming its full-year guidance.

The company's underlying earnings before interest and tax for the last quarter were €6 million, marking a significant milestone since the merger of TUI AG and TUI Travel plc in 2014.

Group revenues also saw a notable increase of 15% year-on-year, driven by improved demand and pricing.

On the upside, luxury car maker Aston Martin Lagonda increased 1.13%, attributed to statements from executive chairman Lawrence Stroll regarding efforts to address the company's significant debt.

Stroll confirmed ongoing discussions with bankers to tackle a looming debt pile, which currently stood at $1.4bn.

Pharmaceutical giant GSK managed gains of 0.95% rise following a broker upgrade from Citi, which shifted its rating from 'neutral' to 'buy'.

Citi cited promising data related to GSK's novel treatment for multiple myeloma, Blenrep, as well as other positive indicators.

The bank's upgraded earnings per share forecasts, reflecting peak Blenrep revenues of about £2.5bn, underscored the newfound confidence in GSK's prospects.

Reporting by Josh White for Sharecast.com.

Market Movers

FTSE 100 (UKX) 7,512.28 -0.81%

FTSE 250 (MCX) 18,923.83 -1.46%

techMARK (TASX) 4,340.39 -1.09%

FTSE 100 - Risers

AstraZeneca (AZN) 9,600.00p 1.04%

GSK (GSK) 1,641.80p 0.95%

Centrica (CNA) 135.55p 0.82%

HSBC Holdings (HSBA) 610.50p 0.35%

Anglo American (AAL) 1,756.00p 0.25%

BP (BP.) 479.75p 0.06%

Hikma Pharmaceuticals (HIK) 1,960.00p 0.03%

Severn Trent (SVT) 2,495.00p 0.00%

Unilever (ULVR) 3,992.50p -0.01%

Smith & Nephew (SN.) 1,096.50p -0.14%

FTSE 100 - Fallers

Barratt Developments (BDEV) 466.10p -4.59%

Taylor Wimpey (TW.) 141.15p -4.39%

Fresnillo (FRES) 471.80p -4.38%

Entain (ENT) 973.80p -4.25%

Persimmon (PSN) 1,361.50p -4.05%

Airtel Africa (AAF) 98.70p -3.89%

Scottish Mortgage Inv Trust (SMT) 779.60p -3.45%

Berkeley Group Holdings (The) (BKG) 4,577.00p -3.44%

RS Group (RS1) 765.00p -3.21%

Ocado Group (OCDO) 519.60p -3.20%

FTSE 250 - Risers

Plus500 Ltd (DI) (PLUS) 1,822.00p 1.62%

Auction Technology Group (ATG) 564.00p 1.44%

SDCL Energy Efficiency Income Trust (SEIT) 57.00p 1.24%

PPHE Hotel Group Ltd (PPH) 1,230.00p 1.23%

easyJet (EZJ) 553.40p 1.21%

JPMorgan Japanese Inv Trust (JFJ) 511.00p 0.99%

Diversified Energy Company (DEC) 915.50p 0.88%

Trustpilot Group (TRST) 185.70p 0.70%

Baltic Classifieds Group (BCG) 229.50p 0.66%

Balanced Commercial Property Trust Limited (BCPT) 78.50p 0.64%

FTSE 250 - Fallers

Crest Nicholson Holdings (CRST) 211.60p -6.37%

UK Commercial Property Reit Limited (UKCM) 63.60p -5.50%

Close Brothers Group (CBG) 402.20p -5.45%

Tritax Eurobox (GBP) (EBOX) 47.60p -4.80%

Great Portland Estates (GPE) 366.60p -4.68%

Mobico Group (MCG) 79.25p -4.58%

Redrow (RDW) 654.00p -4.55%

Bridgepoint Group (Reg S) (BPT) 264.60p -4.20%

IWG (IWG) 190.60p -4.12%

Abrdn (ABDN) 158.90p -3.90%

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.